BioPorto A/S (THOXF)
| Previous Close | 0.4345 |
| Open | 0.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3100 - 0.3100 |
| 52 Week Range | 0.2120 - 0.4345 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 117.694M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
BioPorto A/S Appoints Chief Financial Officer
May 30, 2024Announcement no. 12 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Niels Høy Nielsen as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of August 1, 2024. Niels Høy Nielsen is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from ChemoMetec A/S, a Danish NASDAQ li
- GlobeNewswire
First Quarter 2024: Strong growth in US sales of The NGAL Test
May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced interim financial results for the first three months of 2024 and business progress for the first quarter of 2024. Financial Highlights For the th
- GlobeNewswire
BioPorto A/S Appoints President and CEO of BioPorto Inc.
May 7, 2024News release BioPorto A/S Appoints President and CEO of BioPorto Inc. COPENHAGEN, DENMARK and BOSTON, MA, USA, May 7, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today the appointment of Jeffrey N. Haas as new President and Chief Executive Officer of BioPorto Inc. (US), the fully owned subsidiary of BioPorto, and member of the Group’s Executi
